Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best healthcare stocks under $50 to invest in. Barclays maintained an Overweight rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) on January 30, adjusting the price target on the stock to $38 from $35. It told investors that it updated the company’s model after the fiscal Q4 report, and expressed confidence in the shares at these levels. Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the cheap hot stocks to invest in right now. On January 30, Barclays analyst Glen Santangelo raised the price target for Teva Pharmaceuticals to $38 from $35 with an Overweight rating. Following Teva Pharmaceuticals’ Q4 2025 report, the firm updated its financial model and expressed continued confidence in the stock’s current valuation. A day before that, Scotiabank raised the price target on Teva Pharmaceuticals to $40 from $35 while maintaini ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited's share was trading at $33.07 as of January 28th. TEVA’s trailing and forward P/E were 27.45 and 11.70 respectively according to Yahoo Finance. Jim Cramer Comments On Eli Lilly (LLY)'s Shares After Pfizer CEO's Remarks Teva Pharmaceutical Industries Limited develops, manufactures, markets, ...

Product Launches and Approvals - The company has launched several biosimilar medicines, including TRUXIMA® in 2019, HERZUMA® in 2020, and RANIVISIO® in 2022, with future launches planned for SIMLANDI® in 2024 and SELARSDI in 2025[47]. - A strategic partnership with Samsung Bioepis was announced for the commercialization of EPYSQLI® in the U.S., which launched on April 7, 2025, targeting conditions like paroxysmal nocturnal hemoglobinuria[48]. - A collaboration agreement with Formycon for the commercialization of FYB203 in Europe was established, with Teva leading the marketing under the brand name AHZANTIVE®[49]. - The company received EMA approvals for PONLIMSI® and DEGEVMA® on November 25, 2025, expanding its biosimilar portfolio in Europe[50]. - AJOVY was approved for the preventive treatment of episodic migraine in children aged 6 to 17 years in August 2025, expanding its market reach[62]. - UZEDY was approved as a once-monthly extended-release injectable for bipolar 1 disorder on October 10, 2025, with plans for international launches being evaluated[63]. Financial Performance - Total revenues for 2025 were $17,258 million, with approximately 43% denominated in currencies other than the U.S. dollar, including 20% in euros[514]. - Net revenues for 2025 increased to $17,258 million, up 4.3% from $16,544 million in 2024[552]. - Gross profit for 2025 was $8,938 million, representing a 10.8% increase from $8,064 million in 2024[552]. - Operating income for 2025 was $2,157 million, a significant recovery from an operating loss of $303 million in 2024[552]. - Net income for 2025 was $1,418 million, compared to a net loss of $1,959 million in 2024[552]. - Total assets increased to $40,748 million in 2025, up from $39,326 million in 2024[550]. - Total liabilities decreased to $32,834 million in 2025, down from $33,606 million in 2024[550]. - Cash and cash equivalents rose to $3,556 million in 2025, compared to $3,300 million in 2024[550]. - Earnings per share for 2025 were $1.23, a turnaround from a loss of $1.45 per share in 2024[552]. - Total comprehensive income for 2025 was $2,202 million, compared to a comprehensive loss of $2,467 million in 2024[556]. Research and Development - Teva has over 900 generic products in its pre-approved global pipeline, which includes products at various stages of the approval process[79]. - The innovative R&D pipeline includes key products such as olanzapine LAI for schizophrenia, submitted for regulatory review in December 2025[86]. - Teva's biosimilar products in development include candidates for Xolair® and Entyvio®, with submissions for regulatory review in the U.S.[88]. - Teva's R&D focuses on high-value generics and complex formulations, with a significant investment in API R&D to support timely market introductions[84]. - The company operates a global R&D group responsible for innovative medicines, generic medicines, and biosimilars, enhancing efficiency across operations[77]. Workforce and Employee Engagement - Teva's global workforce as of December 31, 2025, consisted of 33,950 employees, a decrease from 36,830 in 2024 and 37,851 in 2023[113]. - The full-time employee count decreased to 31,173 in 2025 from 33,892 in 2024, while part-time employees were 1,669, and contractors numbered 1,108[114]. - In the United States, the employee count was 4,613, down from 5,104 in 2024, and in Europe, it was 17,390, down from 18,555 in 2024[114]. - Employee engagement survey in 2025 achieved an 83% response rate, with stable satisfaction levels reported across various dimensions[125]. - The company is focused on employee career growth and development, with AI-driven talent development systems expected to be rolled out by the end of 2025[120]. Regulatory and Compliance - The FDA User Fee Reauthorization Act of 2022 allows the FDA to collect user fees from drug manufacturers through fiscal year 2027 to support the product review process[136]. - The Inflation Reduction Act of 2022 requires manufacturers to engage in price-setting discussions with Medicare for certain drugs, with the first set of 10 Part D drugs selected for negotiation announced in August 2024[138]. - The CMS will monitor price increases of drugs under Medicare, imposing rebates if price increases exceed inflation, with penalties for noncompliance set at 125% of the calculated rebate amount[140]. - The European Union's regulatory framework requires marketing authorizations for pharmaceutical products, which can create complexities in pricing and market entry[156]. - The European Commission is reviewing regulatory exclusivity provisions, with potential changes expected by 2026 that could impact market entry for generics[158]. Financial Risk Management - The company has established financial risk management measures to minimize the impact of foreign exchange and interest rate fluctuations[512]. - The company recorded an impairment charge of $726 million for long-lived assets related to a manufacturing facility in Europe for the year ended December 31, 2025[545]. - The total outstanding debt as of December 31, 2025, was $16,807 million, with fixed-rate debt amounting to $16,873 million[528]. - The company manages interest rate risk through various debt instruments, including senior notes and sustainability-linked senior notes[526]. - The company utilizes cross currency swaps and forward contracts to hedge against fluctuations in foreign subsidiaries' net assets[524].

Core Viewpoint - Teva Pharmaceutical Industries Limited is considered one of the best healthcare stocks to buy for 2026, with analysts optimistic about its growth potential despite some revenue headwinds [1][2]. Financial Performance - Teva reported strong Q4 2025 results, with earnings per share (EPS) of $0.96, surpassing the forecast of $0.65, and revenue of $4.71 billion, exceeding expectations of $4.33 billion, aided by a $500 million milestone payment from Sanofi [3]. - However, the company projected lower revenue for 2026, estimating between $16.4 billion and $16.8 billion, along with adjusted EPS of $2.57 to $2.77, reflecting a significant impact from lost sales of its generic Revlimid due to increased competition [3]. Growth Drivers - Teva's innovative portfolio is a key growth driver, with Austedo generating $725 million in U.S. sales in Q4, marking a 40% year-over-year increase. The combined revenue from Austedo, Ajovy, and Uzedy reached $3.1 billion in 2025 and is expected to grow to up to $3.6 billion in 2026 [4]. - Analysts highlight pipeline catalysts, including a potential FDA decision on Olanzapine LAI, which could unlock a $3 billion sales opportunity, supporting Teva's growth narrative [1][2]. Market Position - Teva is recognized as a global leader in generic and specialty medicines, focusing on the development, manufacturing, and marketing of drugs across various therapeutic areas, including central nervous system, respiratory, and oncology [5].

Company Overview - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the world's largest generic drug makers, producing medical products including generic pills, inhalers, and treatments for conditions like migraines and cancer [2]. Stock Performance - The stock of Teva has experienced a significant turnaround, gaining nearly 400% from its 2022 lows following a leadership change with Richard Francis taking over at the beginning of 2023 [1]. - Over the past 12 months, Teva's stock has increased by 54% [1]. - Despite a quarterly report that exceeded expectations, the company's full-year forecast was perceived as slightly light, leading to an initial stock drop of 9% after the announcement [1]. - The stock stabilized after the conference call and finished the day up more than 2% [1].

Core Viewpoint - Teva Pharmaceutical Industries is experiencing a positive outlook due to strong financial performance and an increased price target from Scotiabank, indicating potential growth opportunities for investors [2][4][5] Financial Performance - Teva reported a significant increase in its fourth-quarter profit, driven by strong sales of branded drugs and a milestone payment for treatments related to ulcerative colitis and Crohn's disease [2][5] - The company's current market capitalization is approximately $37.31 billion, reflecting its substantial presence in the pharmaceutical industry [4] Stock Performance - The current stock price of TEVA is $32.54, which has seen a decrease of 2.03% with a change of $0.68 [3][5] - TEVA's stock has fluctuated between a low of $32.19 and a high of $33.43 today, with the highest price over the past year being $33.43 and the lowest at $12.47, indicating volatility and growth potential [3][5] Analyst Ratings - Scotiabank maintains an "Outperform" rating for TEVA and has raised its price target from $35 to $40, reflecting an optimistic outlook for the company's future performance [2][5] - The trading volume for TEVA today is 2,763,304 shares, indicating active investor interest [4]

Key Takeaways TEVA posted Q4 adjusted EPS of 96 cents and $4.71B in revenues, with both beating consensus estimates.TEVA's results were driven by a $500M Sanofi milestone and strong branded drug sales, led by Austedo.TEVA guided 2026 revenues of $16.4-$16.8B with continued momentum across Austedo, Ajovy and Uzedy.Teva Pharmaceutical Industries (TEVA) reported fourth-quarter 2025 adjusted earnings of 96 cents per share, which comprehensively beat the Zacks Consensus Estimate of 65 cents. Adjusted earnings ro ...

Greenlight Capital, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Greenlight Capital’s investment strategy focuses on constructing a bottom-up portfolio comprising undervalued long positions and overvalued short positions, while also including a macro book to hedge risks and capture insights. The Partnership returned 9.0% (net) in 2025 compared to 17.9% for the S&P 500 index. In contrast, it returned 8.5% in Q4, compared to 2 ...

Teva Stock Slides On Guidance Surprise Despite Fourth-Quarter Beat | Investor's Business DailyANALYSIS: [AI Bubble Or Boom? Wall Street Weighs In]Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience.---Teva stock tumbled Wednesday on surprisingly light guidance for 2026 following a decisive fourth-quarter beat. For the year, Teva Pharmaceutical (TEVA) expects to earn an adjusted $2.57 to $2.77 per share on $1 ...